Endo International’s board of directors has named Paul V. Campanelli president and chief executive officer (CEO), effective immediately. Mr. Campanelli currently serves as president of Endo’s generic and over-the-counter drug businesses, Par Pharmaceutical. Campanelli, who will also join Endo’s board of directors, succeeds Rajiv De Silva, who has stepped down as president, CEO and a member of the board.

Campanelli joined Endo in 2015 following Endo’s acquisition of Par Pharmaceutical, where he had served as CEO since 2012. Since joining Endo, Campanelli has overseen the company’s US generic pharmaceuticals business.

Prior to becoming CEO of Par in 2012, Campanelli served as chief operating officer of Par Pharmaceutical. Previously, he held roles of increasing responsibility at Par, including president, Par Generics, and executive vice president, business development and licensing for branded and generic products. Campanelli has more than 25 years of experience in the generics and branded pharmaceutical industry.

Source: Endo International